We report 2 cases of cutaneous pseudolymphoma arising after injection of a granulocyte macrophage (GM)-colony stimulating factor (GM-CSF)–producing pancreatic tumor cell vaccine (GVAX).
A man in his 20s with metastatic pancreatic adenocarcinoma received an ipilimumab infusion and subcutaneous injections of GVAX as part of a phase 2 trial (NCT01896869). One week after the first GVAX injections, he developed intensely pruritic lesions surrounding the injection sites on the bilateral dorsal thighs and right upper arm. Examination revealed erythematous papulovesicles and concentric yellow-orange plaques surrounding injection sites (Figure 1A).
Staser K, Abner S, Anadkat M, Musiek A, Schaffer A. Injection-Site Cutaneous Pseudolymphoma Induced by a GM-CSF–Producing Tumor Cell Vaccine. JAMA Dermatol. 2017;153(4):332–334. doi:10.1001/jamadermatol.2016.4988
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: